Evidence map›Paper›PMID 32131766›Full record

ArticleBMC cancer2020

Incidence of advanced-stage breast cancer in regular participants of a mammography screening program: a prospective register-based study.

Laura Khil, Jan Heidrich, Ina Wellmann, Vanessa Kääb-Sanyal, Stefanie Weigel, Walter Heindel, Hans-Werner Hense, Oliver Heidinger

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Laura KhilCancer Registry North Rhine-Westphalia, Gesundheitscampus 10, 44801, Bochum, Germany. laura.khil@krebsregister.nrw.de.ORCID http://orcid.org/0000-0001-5600-907X
Jan HeidrichCancer Registry North Rhine-Westphalia, Gesundheitscampus 10, 44801, Bochum, Germany.
Ina WellmannCancer Registry North Rhine-Westphalia, Gesundheitscampus 10, 44801, Bochum, Germany.
Vanessa Kääb-SanyalKooperationsgemeinschaft Mammographie, Berlin, Germany.
Stefanie WeigelInstitute of Clinical Radiology, University Hospital Münster, Münster, Germany.
Walter HeindelInstitute of Clinical Radiology, University Hospital Münster, Münster, Germany.
Hans-Werner HenseCancer Registry North Rhine-Westphalia, Gesundheitscampus 10, 44801, Bochum, Germany.
Oliver HeidingerCancer Registry North Rhine-Westphalia, Gesundheitscampus 10, 44801, Bochum, Germany.
University Hospital Münster · DEUniversity of Münster · DEKrebsregister Saarland · DEUniversität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe European Guidelines for breast cancer screening suggest that the impact of population-based mammography screening programmes (MSP) may be assessed using the relative reduction in the incidence of advanced breast cancer (ABC, that is, stage UICC II and higher) as a surrogate indicator of screening effectiveness.

methodsThis prospective, population register-based study contained individual data of 1,200,246 women (aged 50-69 years) who attended the initial prevalence screening between 2005 and 2009. Of them, 498,029 women returned for the regular (i.e., within 24 months) first subsequent, and 208,561 for the regular second subsequent incidence screenings. The incidence rate of ABC was calculated for the 24-months period following, but not including, the initial screening by incorporating all interval ABCs and all ABCs detected at the regular first incidence screening; the ABC rate for the second 24-months period was determined in the same way, including ABCs detected in the interval after the first and, respectively, at the second incidence screening. The relative reduction in the ABC incidence was derived by comparing the age-standardized rates in these two periods with an age-standardized reference incidence rate, observed in the target population before the MSP implementation. The strengths and weaknesses of this particular study design were contrasted with a recently published checklist of main methodological problems affecting studies of the effect of MSP on ABC incidence.

resultsThe age-standardized ABC incidence rate was 291.6 per 100,000 women for the 24-months period subsequent to the initial screening, and 275.0/100,000 for the 24-months period following the first subsequent screening. Compared to the 2-year incidence of 349.4/100,000 before the start of the MSP, this amounted to a relative reduction of 16.5 and 21.3%, respectively, in the incidence of ABC among regular MSP participants.

conclusionsThe design employed in this study avoids some of the substantial methodological limitations that compromised previous observational studies. Nevertheless, specific limitations prevail that demand a cautious interpretation of the results. Therefore, the study findings, indicating a reduction in ABC for regular MSP participants, need to be followed with respect to potential impacts on breast cancer mortality rates.

Indexed as

AgedBreast NeoplasmsEarly Detection of CancerFemaleHumansIncidenceMammographyMiddle AgedNeoplasm StagingProspective StudiesRegistriesAdvanced breast cancer - mammography screening programme - incidence rate reduction - population-based cancer registry

Identifiers

PMID32131766
PMCPMC7057462
OpenAlexW3010372369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.